ELUTIA INC. — fact timeline

ELUTIA INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a), 5810(c)(3)(A)).

“November 7, 2025 that it no longer satisfied Nasdaq Listing Rule 5550(a), which requires the Company to maintain a minimum bid price of $1.00 per share (the “ Bid Price Rule ”) for continued listing on The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of the notification, or until May 6, 2026, to regain compliance with the Bid Price Rule, which requires that the closing bid price of the Common Stock be at least $1.00 for a minimum of 10 consecutive business days (unless the Staff exercises its discretion”

ELUTIA INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)).

“November 7, 2025 that it no longer satisfied Nasdaq Listing Rule 5550(a), which requires the Company to maintain a minimum bid price of $1.00 per share (the “ Bid Price Rule ”) for continued listing on The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of the notification, or until May 6, 2026, to regain compliance with the Bid Price Rule, which requires that the closing bid price of the Common Stock be at least $1.00 for a minimum of 10 consecutive business days (unless the Staff exercises its discretion”

ELUTIA INC. received a nasdaq deficiency notice notice regarding late filing (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)).

“November 7, 2025, Elutia Inc., a Delaware corporation (the “Company” or “Elutia”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”), was below $1.00 per share, which is the minimum closing bid price (the “Minimum Bid Price”) required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Notice”). This Notice has no im”

ELUTIA INC. completed a disposition involving Boston Scientific Corporation and Cardiac Pacemakers, Inc. (closed 2025-10-01).

“On October 1, 2025, the parties completed the sale of the CIED Business.”

ELUTIA INC. amended term loan of $25.0 million with SWK Funding LLC at accrued and unpaid interest due and owing to Lenders on the payment date in Augu.

“to time party thereto (as amended and supplemented from time to time, the “SWK Facility”). The SWK Facility provides for a senior secured term loan in an aggregate amount of $25.0 million (the “Term Loan”). The Amendment, among other things, provided that the following amounts will be capitalized into the unpaid principal balance of the Term Loan: (i) all accrued”

ELUTIA INC. reported first quarter ended March 31, 2024 results: revenue $6.7 million, net income $18.0 million.

“second half of this year. First Quarter 2024 Financial Results For the three-month period ended March 31, 2024, as compared to the same period of 2023: · Overall net sales were $6.7 million, an increase of 5%. · Net sales of SimpliDerm were $3.6 million, compared to $2.3 million, an increase of 55%, as customer awareness and acceptance accelerated within the $1.6”

ELUTIA INC. amended Second Amendment with SWK Funding LLC (effective 2024-03-27).

“On March 27, 2024, Elutia Inc., a Delaware corporation (the “Company”), entered into a Second Amendment (the “Amendment”) to that certain Credit Agreement, dated as of August 10, 2022, by and among the Company, as Borrower, SWK Funding LLC, as Agent, and the lenders from time to time party thereto (as amended and supplemented from time to time, the “SWK Facility”).”

ELUTIA INC. reported financial results for the fourth quarter and full year ended December 31, 2023.

“issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023.”